<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To report a case of a successful <z:hpo ids='HP_0000518'>cataract</z:hpo> surgery outcome in a patient with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) without postoperative <z:mp ids='MP_0001845'>inflammation</z:mp> under infliximab therapy </plain></SENT>
<SENT sid="1" pm="."><plain>CASE: A 40-year-old man who had frequent episodes of <z:e sem="disease" ids="C0020641" disease_type="Disease or Syndrome" abbrv="">hypopyon</z:e> <z:hpo ids='HP_0000554'>uveitis</z:hpo> despite immunosuppressive therapy underwent <z:hpo ids='HP_0000518'>cataract</z:hpo> surgery </plain></SENT>
<SENT sid="2" pm="."><plain>Infliximab (5 mg/kg) was given intravenously to prevent <z:mp ids='MP_0001845'>inflammation</z:mp> during the perioperative period </plain></SENT>
<SENT sid="3" pm="."><plain>After the initial administration, infliximab was given at 2 and 6 weeks, and then it was given at 8 weeks intervals thereafter </plain></SENT>
<SENT sid="4" pm="."><plain>The patient underwent <z:hpo ids='HP_0000518'>cataract</z:hpo> surgery in both eyes at the midpoint of the 8 weeks duration schedule with an uneventful postoperative clinical course for up to 12 months except for the contraction of the anterior capsule in both eyes and <z:e sem="disease" ids="C1444680" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">posterior capsule opacification</z:e> in 1 eye </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Infliximab therapy may be effective when performing <z:hpo ids='HP_0000518'>cataract</z:hpo> surgery on BD patients who have uncontrollable <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
</text></document>